RT @ejdein1: #EULAR2021 LB0001. Mavrilimumab (blocks GM-CSF alpha) phase2 trial in non-vented patients w/ #COVID19 : â
Tweet Content
#EULAR2021 LB0001. Mavrilimumab (blocks GM-CSF alpha) phase2 trial in non-vented patients w/ #COVID19 :
⭐️⬇️ mortality and ventilation at day 29
⭐️61% reduction in death (HR 0.39)
⭐️No drug related SAEs, no dose-related AEs
@Rheumnow https://t.co/9UOi3xF7Re
Show on Archive Page
On
Display in Search Results
On
PDQ
Off